ES2538835T3 - Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica - Google Patents
Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica Download PDFInfo
- Publication number
- ES2538835T3 ES2538835T3 ES10729069.4T ES10729069T ES2538835T3 ES 2538835 T3 ES2538835 T3 ES 2538835T3 ES 10729069 T ES10729069 T ES 10729069T ES 2538835 T3 ES2538835 T3 ES 2538835T3
- Authority
- ES
- Spain
- Prior art keywords
- botulinum toxin
- composition
- soft tissue
- treatment
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 186
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 186
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 181
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 130
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 127
- 238000011282 treatment Methods 0.000 title claims abstract description 107
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 69
- 230000003902 lesion Effects 0.000 title description 14
- 206010024453 Ligament sprain Diseases 0.000 claims abstract description 65
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 208000010040 Sprains and Strains Diseases 0.000 claims abstract description 30
- 206010050031 Muscle strain Diseases 0.000 claims abstract description 23
- 210000003041 ligament Anatomy 0.000 claims abstract description 14
- 210000003205 muscle Anatomy 0.000 claims abstract description 14
- 210000003195 fascia Anatomy 0.000 claims abstract description 10
- 210000002435 tendon Anatomy 0.000 claims abstract description 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 16
- 239000003246 corticosteroid Substances 0.000 claims description 11
- 238000007906 compression Methods 0.000 claims description 8
- 239000011505 plaster Substances 0.000 claims description 8
- 230000006835 compression Effects 0.000 claims description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000399 orthopedic effect Effects 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 69
- 229940089093 botox Drugs 0.000 description 60
- 208000002193 Pain Diseases 0.000 description 44
- 230000036407 pain Effects 0.000 description 44
- 208000002240 Tennis Elbow Diseases 0.000 description 41
- 239000007924 injection Substances 0.000 description 33
- 238000002347 injection Methods 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 32
- 239000000902 placebo Substances 0.000 description 32
- 201000011275 Epicondylitis Diseases 0.000 description 31
- 238000011156 evaluation Methods 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 239000003814 drug Substances 0.000 description 26
- 230000006378 damage Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 208000014674 injury Diseases 0.000 description 24
- 230000002411 adverse Effects 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 22
- 208000026137 Soft tissue injury Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 206010060820 Joint injury Diseases 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229940094657 botulinum toxin type a Drugs 0.000 description 8
- 229960001334 corticosteroids Drugs 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000002483 medication Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 210000003423 ankle Anatomy 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 210000000707 wrist Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229960004716 idoxuridine Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000561734 Celosia cristata Species 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 210000001520 comb Anatomy 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000022542 ankle injury Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229940112646 myobloc Drugs 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229940127558 rescue medication Drugs 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 241001125671 Eretmochelys imbricata Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000722985 Fidia Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000016593 Knee injury Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 238000002567 electromyography Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 231100000654 protein toxin Toxicity 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 206010073713 Musculoskeletal injury Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- 101000822797 Naja naja Long neurotoxin 5 Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 241000469816 Varus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 208000024764 elbow pain Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229940018991 hyalgan Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000025743 negative regulation of exocytosis Effects 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 108010010958 snake venom neurotoxin F Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14294109P | 2009-01-07 | 2009-01-07 | |
| US142941P | 2009-01-07 | ||
| PCT/CA2010/000008 WO2010078648A1 (en) | 2009-01-07 | 2010-01-06 | Treatment of soft tissue injury using hyaluronic acid and botulinum toxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2538835T3 true ES2538835T3 (es) | 2015-06-24 |
Family
ID=42311846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10729069.4T Active ES2538835T3 (es) | 2009-01-07 | 2010-01-06 | Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9072779B2 (enExample) |
| EP (1) | EP2381956B9 (enExample) |
| JP (2) | JP5688031B2 (enExample) |
| AU (1) | AU2010204445B2 (enExample) |
| CA (1) | CA2749034C (enExample) |
| ES (1) | ES2538835T3 (enExample) |
| WO (1) | WO2010078648A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2743746C2 (ru) * | 2016-03-02 | 2021-02-25 | Мерц Фарма Гмбх Энд Ко. Кгаа | Композиция, содержащая ботулинический токсин |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| JP6357228B2 (ja) * | 2013-07-10 | 2018-07-11 | マトリックス バイオロジー インスティテュート | 高い弾性を有するヒアルロナンの組成物およびその使用 |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| WO2015115113A1 (ja) * | 2014-01-31 | 2015-08-06 | テルモ株式会社 | 穿刺補助器具および穿刺器具セット |
| HUE054874T2 (hu) | 2015-09-24 | 2021-10-28 | Matrix Biology Inst | Magas elaszticitású hialuronán készítmények és alkalmazási eljárások |
| WO2018216974A2 (ko) * | 2017-05-24 | 2018-11-29 | 주식회사 에이티지씨 | 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법 |
| WO2018233813A1 (en) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| US11155802B2 (en) | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US7300412B2 (en) * | 2002-05-10 | 2007-11-27 | Hospital For Joint Diseases | Methods for therapeutic treatment of carpal tunnel syndrome |
| US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| NZ540425A (en) * | 2002-12-20 | 2009-03-31 | Botulinum Toxin Res Ass Inc | Pharmaceutical botulinum toxin compositions |
| SI1677806T1 (sl) | 2003-10-09 | 2009-06-30 | Robert John Petrella | Postopki za zdravljenje akutnega in s preobremenitvijo povzročenega zvina in natega z uporabo hialuronske kisline |
| KR20070034128A (ko) * | 2004-07-22 | 2007-03-27 | 코닌클리즈케 필립스 일렉트로닉스 엔.브이. | 통신 시스템 및 방법과, 이들의 사용 및 이동 노드 |
| WO2006020208A2 (en) | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition whit a botulinum neurotoxin |
| PL1853303T3 (pl) * | 2005-02-14 | 2016-05-31 | Dpm Therapeutics Corp | Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania |
| FR2896693B1 (fr) | 2006-01-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition comprenant plusieurs toxines botuliques |
-
2010
- 2010-01-06 ES ES10729069.4T patent/ES2538835T3/es active Active
- 2010-01-06 US US12/683,351 patent/US9072779B2/en active Active
- 2010-01-06 AU AU2010204445A patent/AU2010204445B2/en active Active
- 2010-01-06 JP JP2011543955A patent/JP5688031B2/ja active Active
- 2010-01-06 EP EP10729069.4A patent/EP2381956B9/en active Active
- 2010-01-06 WO PCT/CA2010/000008 patent/WO2010078648A1/en not_active Ceased
- 2010-01-06 CA CA2749034A patent/CA2749034C/en active Active
-
2014
- 2014-08-07 JP JP2014161022A patent/JP2014208705A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2743746C2 (ru) * | 2016-03-02 | 2021-02-25 | Мерц Фарма Гмбх Энд Ко. Кгаа | Композиция, содержащая ботулинический токсин |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010204445B2 (en) | 2015-09-03 |
| CA2749034C (en) | 2019-01-15 |
| AU2010204445A1 (en) | 2011-07-28 |
| EP2381956B9 (en) | 2016-11-23 |
| CA2749034A1 (en) | 2010-07-15 |
| WO2010078648A1 (en) | 2010-07-15 |
| JP5688031B2 (ja) | 2015-03-25 |
| JP2012514579A (ja) | 2012-06-28 |
| EP2381956B1 (en) | 2015-04-22 |
| EP2381956A4 (en) | 2013-01-02 |
| EP2381956A1 (en) | 2011-11-02 |
| US20100172940A1 (en) | 2010-07-08 |
| JP2014208705A (ja) | 2014-11-06 |
| US9072779B2 (en) | 2015-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2538835T3 (es) | Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica | |
| Pavelka et al. | Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study | |
| Sun et al. | Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study | |
| JP2016185989A (ja) | ヒアルロン酸を使用する急性及び過用性の捻挫及び筋違いの治療方法 | |
| Witteveen et al. | A prospective multi-centre, open study of the safety and efficacy of hylan GF 20 (Synvisc®) in patients with symptomatic ankle (talo-crural) osteoarthritis | |
| Hsieh et al. | Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis | |
| CN105960230B (zh) | 水基辣椒素制剂及制备方法和应用 | |
| Lee et al. | Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: open-label, randomized, multicentre clinical trial | |
| Kim et al. | Does hyaluronate injection work in shoulder disease in early stage? A multicenter, randomized, single blind and open comparative clinical study | |
| Borras-Verdera et al. | Efficacy and safety of a single intra-articular injection of 2% hyaluronic acid plus mannitol injection in knee osteoarthritis over a 6-month period | |
| Lee et al. | Effect of hypertonic saline in intra-articular hydraulic distension for adhesive capsulitis | |
| Petrella et al. | Long-term efficacy and safety of periarticular hyaluronic acid in acute ankle sprain | |
| RU2734159C1 (ru) | Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием | |
| Witteveen et al. | The optimal injection technique for the osteoarthritic ankle: a randomized, cross-over trial | |
| RU2299733C1 (ru) | Способ лечения дегенеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических спаечных процессов | |
| ES2447829T3 (es) | Combinación para el tratamiento de la osteoartritis | |
| Lynen | Treatment of chronic tendinopathies with peritendinous hyaluronan injections under sonographic guidance—an interventional, prospective, single-arm, multicenter study, Dtsch | |
| Stitik et al. | Synvisc®® in knee osteoarthritis | |
| Petrella et al. | Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee | |
| US20070142480A1 (en) | Alleviation of pain in osteoarthritis by means of intra-articular implantation of perfluorodecalin. | |
| RU2436584C1 (ru) | Способ лечения дегеративно-дистрофических заболеваний опорно-двигательного аппарата и посттравматических спаечных процессов | |
| Sun et al. | Hyaluronate for the Treatment of Ankle Osteoarthritis |